• +1-646-491-9876
    • +91-20-67278686

    Search

    Caspase 6 Pipeline Review H1 2017

    Caspase 6 Pipeline Review H1 2017

    • Report Code ID: RW0001851090
    • Category Life Sciences
    • No. of Pages 48
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Caspase 6 - Pipeline Review, H1 2017'; Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.

    The report 'Caspase 6 - Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency) , Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD) , Non-Alcoholic Steatohepatitis (NASH) , Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
    - The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Overview
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Companies Involved in Therapeutics Development
    Conatus Pharmaceuticals Inc
    New World Laboratories Inc
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Drug Profiles
    ED-11 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emricasan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IDN-7314 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NWL-154 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Dormant Products
    Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Product Development Milestones
    Featured News & Press Releases
    Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
    Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
    Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
    May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
    Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
    Apr 15, 2016: Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
    Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
    Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis
    Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis
    Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
    Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
    Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
    Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
    Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
    Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Conatus Pharmaceuticals Inc, H1 2017
    Pipeline by New World Laboratories Inc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Conatus Pharmaceuticals Inc
    New World Laboratories Inc

    Request for Sample

    Report Url http://www.reportsweb.com//caspase-6-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//caspase-6-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//caspase-6-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments